Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using 177Lu-iPSMA and 177Lu-DOTATOC: Experience after 905 Treatment Doses.
Luna-Gutiérrez M, Hernández-Ramírez R, Soto-Abundiz A, García-Pérez O, Ancira-Cortez A, López-Buenrostro S, Gibbens-Bandala B, Soldevilla-Gallardo I, Lara-Almazán N, Rojas-Pérez M, Ocampo-García B, Azorín-Vega E, Santos-Cuevas C, Ferro-Flores G.
Luna-Gutiérrez M, et al. Among authors: gibbens bandala b.
Pharmaceutics. 2023 Jul 20;15(7):1988. doi: 10.3390/pharmaceutics15071988.
Pharmaceutics. 2023.
PMID: 37514174
Free PMC article.